These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8549285)

  • 21. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I; Robbins M; Viljoen L; Brown DF
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro antibacterial activities of broad spectrum quinolones against clinical bacterial isolates].
    Ishii Y; Ohno A; Yamaguchi K
    Jpn J Antibiot; 1994 Jan; 47(1):22-8. PubMed ID: 8114270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J; Fernandes ML; Serrano N;
    Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New quinolones for the treatment of community-acquired pneumonia--pro].
    Zimmerli S
    Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
    [No Abstract]   [Full Text] [Related]  

  • 32. [Microbiological evaluation of antibiotics for empirical therapy of community-acquired infections of the lower respiratory tract].
    Bogdanov MB; Chernen'kaia TV
    Antibiot Khimioter; 2000; 45(10):15-8. PubMed ID: 11212394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.
    Chidiac C; Mouton Y
    Infection; 1991; 19 Suppl 7():S365-71. PubMed ID: 1804785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996.
    Felmingham D; Washington J
    J Chemother; 1999 Feb; 11 Suppl 1():5-21. PubMed ID: 10207769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of fluoroquinolones in respiratory tract infections.
    Grossman RF
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():59-62. PubMed ID: 9484874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of fluoroquinolones in lower respiratory tract infections.
    Vellend H
    Clin Invest Med; 1989 Feb; 12(1):39-43. PubMed ID: 2920482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections.
    Stein GE; Havlichek DH
    Pharmacotherapy; 1997; 17(6):1139-47. PubMed ID: 9399598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinolone generations: natural history or natural selection?
    Ball P
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():17-24. PubMed ID: 10997595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.